Olmesartan Medoxomil / Amlodipine / Hctz Win Medica (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan Medoxomil / Amlodipine / Hctz Win Medica is used in the management of hypertension, a condition characterized by elevated arterial pressure.

• Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Hypertensive heart disease: helps prevent left‑ventricular hypertrophy and related complications.
• Hypertensive chronic kidney disease: assists in slowing renal function decline associated with high blood pressure.

• The combination works by three complementary actions: olmesartan medoxil blocks the angiotensin II type‑1 receptor, preventing vasoconstriction; amlodipine inhibits calcium influx into vascular smooth‑muscle cells, producing arterial dilation; and hydrochlorothiazide increases urinary sodium and water excretion, decreasing plasma volume. Together these effects lower systemic vascular resistance and cardiac output, resulting in reduced arterial pressure.

Common Side Effects

• Dizziness or light‑headedness, especially after the first dose.
• Peripheral edema, often noticeable in the ankles or lower legs.
• Headache, typically mild and transient.
• Flushing or a sensation of warmth.
• Fatigue or general tiredness.
• Increased urination due to the diuretic component.

Serious or Rare Side Effects

• Severe hypotension leading to fainting or shock.
• Acute kidney injury manifested by sudden rise in serum creatinine.
• Electrolyte disturbances such as hyponatremia or hyperkalemia.
• Angio‑edema affecting the face, lips, tongue or airway.
• Liver enzyme elevations indicating possible hepatotoxicity.
• Blood disorders such as agranulocytosis or thrombocytopenia.

Before starting therapy, patients should be assessed for renal function, electrolyte balance, and cardiovascular status.

• Monitor blood pressure: ensure adequate control without excessive lowering.
• Review kidney function: adjust dosing if creatinine clearance is reduced.
• Check electrolytes: watch for sodium, potassium, and magnesium abnormalities.
• Evaluate for heart failure: avoid rapid volume depletion in decompensated patients.
• Counsel on orthostatic dizziness: advise rising slowly from sitting or lying positions.
• Store at ambient temperature: keep below 25°C, in the original container, protected from moisture and light.

Olmesartan Medoxomil / Amlodipine / Hctz Win Medica may interact with several medicines that influence blood pressure or electrolyte balance.

Major Interactions (Avoid)

• ACE inhibitors or other ARBs: additive risk of hyperkalaemia and renal impairment.
• Potassium‑rich supplements or salt substitutes: may cause dangerous hyperkalaemia.
• Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): increase amlodipine levels.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive effect and affect renal function.
• Lithium: thiazide component may raise lithium concentrations.
• Antidiabetic drugs: diuretic‑induced volume changes may alter glucose control.
• Alcohol: may enhance hypotensive effect.
• Digoxin: thiazide‑induced electrolyte shifts can predispose to digoxin toxicity.